IRF4/MUM1 expression is associated with poor survival outcomes in patients with peripheral T-cell lymphoma. - Wikidata - wikimedia - TriplyDB

IRF4/MUM1 expression is associated with poor survival outcomes in patients with peripheral T-cell lymphoma.

IRF4/MUM1 expression is associated with poor survival outcomes in patients with peripheral T-cell lymphoma.

http://www.wikidata.org/entity/Q33702340

about

IRF4/MUM1 expression is associated with poor survival outcomes in patients with peripheral T-cell lymphoma.

http://www.wikidata.org/entity/Q33702340

description

2017 nî lūn-bûn

@nan

2017 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի մարտին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

IRF4/MUM1 expression is associ ...... th peripheral T-cell lymphoma.

@ast

IRF4/MUM1 expression is associ ...... th peripheral T-cell lymphoma.

@en

type

label

IRF4/MUM1 expression is associ ...... th peripheral T-cell lymphoma.

@ast

IRF4/MUM1 expression is associ ...... th peripheral T-cell lymphoma.

@en

prefLabel

IRF4/MUM1 expression is associ ...... th peripheral T-cell lymphoma.

@ast

IRF4/MUM1 expression is associ ...... th peripheral T-cell lymphoma.

@en

P1433

Q33702340-F18B1C26-36DC-4B28-9A71-24F4BC77403D

P1476

Q33702340-6555F950-F008-4E10-B17E-EA781A9E6EF3

P2093

Q33702340-76A7054B-F63A-4B76-97F1-60B443852606

Q33702340-961CD057-2321-4CC6-AF68-58B67F32A048

Q33702340-9D2E8C58-27C1-4753-B72C-4B5DB4B350E6

Q33702340-D3B7436B-AD91-4AE1-BC98-F74B9A1D5867

Q33702340-D95C101A-DF5D-4E8A-883E-062083E82D1F

P2860

Q33702340-08802FD2-F484-4043-99D9-2DC6CF531162

Q33702340-2B783EA4-CAFA-43FC-95CA-40698CE34BE2

Q33702340-3F58D729-254A-4C86-B0A0-399E15EA4A54

Q33702340-48E3D673-B8BF-42FB-89AF-193D1E5975AC

Q33702340-5E603E99-9179-47DA-AA5A-55F340840450

Q33702340-5F774D2B-28EF-402B-8886-2B3419442FB6

Q33702340-73D1B088-84BE-4B2C-830F-3600D46131A0

Q33702340-7C384F63-DE32-4442-A2D1-45925B9EA849

Q33702340-8650154F-280C-4F54-BB3D-3E8CC6B659B2

Q33702340-931F7979-D080-425A-BD91-86B2F868BE74

P304

Q33702340-D23D9C09-0E7F-4ABE-9AB5-4ED3BFA38DCB

P31

Q33702340-809C8E56-8F62-4AB8-8356-A0C46F5EDF5F

P356

Q33702340-EF720345-F5CC-4227-80BF-532E3AF32F69

P433

Q33702340-01DF981E-8532-4CFE-B342-B6C8515B7316

P478

Q33702340-215F2C96-50B1-49C1-891F-0485942AB15D

P577

Q33702340-F189CC98-BEB2-4838-A60E-ABD3672E22CC

P698

Q33702340-9D45F71B-79A8-4961-9698-C4F6D520AACA

P932

Q33702340-C7FB3380-6F4D-41A5-87F5-B1C1F27AEA47

P356

P1433

Journal of Cancer

P1476

IRF4/MUM1 expression is associ ...... th peripheral T-cell lymphoma.

@en

P2093

Ha Young Park

http://www.w3.org/2001/XMLSchema#string

Mi Hwa Heo

http://www.w3.org/2001/XMLSchema#string

Seok Jin Kim

http://www.w3.org/2001/XMLSchema#string

Won Seog Kim

http://www.w3.org/2001/XMLSchema#string

Young Hyeh Ko

http://www.w3.org/2001/XMLSchema#string

P2860

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins

Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry.

Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma.

A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.

The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas.

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response.

International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.

The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphoma.

P304

1018-1024

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7150/JCA.17358

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28529614

http://www.w3.org/2001/XMLSchema#string

P932

5436254

http://www.w3.org/2001/XMLSchema#string